| Literature DB >> 16735084 |
Laura J Peek1, Duane T Brandau, LaToya S Jones, Sangeeta B Joshi, C Russell Middaugh.
Abstract
Region II of the erythrocyte-binding antigen (EBA-175 RII) has been identified as a promising target for a malaria vaccine. A systematic approach to identify optimal preformulation conditions of a non-glycosylated (NG) antigen, EBA-175 RII-NG, has been developed. This approach consists of development of an empirical temperature/pH phase diagram, high throughput stabilizer screening and aluminum salt adjuvant adsorption studies. Using these physical methods, we developed a stable formulation for EBA-175 RII-NG at pH 6.0 with sucrose and Brij 35 as stabilizers and Adju-Phos as an adjuvant. This approach should be generally applicable to guiding the development of stable vaccine formulations.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16735084 DOI： 10.1016/j.vaccine.2006.04.067
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641